FDA should put resources in better enforcement of compounding rules

04/22/2013 | Washington Post, The

The FDA should do more to establish a clear line between drug manufacturing and compounding, write Michael Carome and Sarah Sorscher of Public Citizen's Health Research Group in response to statements by FDA Commissioner Dr. Margaret Hamburg and agency official Howard Sklamberg. Compounders that act as manufacturers should be regulated as manufacturers, which is well within the FDA's authority, Sorscher and Carome write.

View Full Article in:

Washington Post, The

Published in Brief: